Capital One Financial upgraded shares of Kodiak Sciences (NASDAQ:KOD – Free Report) from an equal weight rating to an overweight rating in a research report released on Friday, MarketBeat reports. The firm currently has $12.00 price objective on the stock, up from their prior price objective of $7.00.
A number of other brokerages have also recently issued reports on KOD. Jefferies Financial Group cut Kodiak Sciences from a buy rating to a hold rating in a report on Monday, July 24th. Chardan Capital cut Kodiak Sciences from a buy rating to a neutral rating in a report on Tuesday, July 25th. UBS Group cut Kodiak Sciences from a buy rating to a neutral rating and lowered their target price for the stock from $15.00 to $4.00 in a report on Thursday, July 27th. Finally, JPMorgan Chase & Co. cut Kodiak Sciences from a neutral rating to an underweight rating in a report on Monday, July 24th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Kodiak Sciences presently has a consensus rating of Hold and an average target price of $8.67.
Kodiak Sciences Stock Down 2.4 %
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC bought a new position in shares of Kodiak Sciences in the third quarter valued at approximately $81,000. Newtyn Management LLC lifted its holdings in shares of Kodiak Sciences by 62.5% in the third quarter. Newtyn Management LLC now owns 1,608,694 shares of the company’s stock valued at $2,896,000 after purchasing an additional 618,991 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Kodiak Sciences by 1,173.9% in the third quarter. Tower Research Capital LLC TRC now owns 16,994 shares of the company’s stock valued at $31,000 after purchasing an additional 15,660 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Kodiak Sciences by 253.6% in the third quarter. Acadian Asset Management LLC now owns 1,636,621 shares of the company’s stock valued at $2,945,000 after purchasing an additional 1,173,832 shares in the last quarter. Finally, Hsbc Holdings PLC lifted its holdings in shares of Kodiak Sciences by 159.1% in the third quarter. Hsbc Holdings PLC now owns 40,795 shares of the company’s stock valued at $74,000 after purchasing an additional 25,053 shares in the last quarter. Institutional investors own 80.99% of the company’s stock.
Kodiak Sciences Company Profile
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
- Five stocks we like better than Kodiak Sciences
- Are Stock Buybacks Good for the Average Investor?
- The most upgraded stocks in November have two things in common
- How to Invest in Apparel Stocks
- Monday.com rocked earnings like it’s the weekend
- How to Invest in E-Commerce: A Guide
- Plan to own one retailer? Make it this one
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.